Hola,
Are you new here?

I have an account

¿Te ayudamos?

Ejemplos de búsqueda

Vídeos Explicativos

ERA4TB

financed

Closed

EUROPEAN REGIMEN ACCELERATOR FOR TUBERCULOSIS

The European Regimen Accelerator for Tuberculosis (ERA4TB) has the explicit goal of developing a new combination therapy to treat all forms of TB starting from ~20 leads and drug candidates provided by EFPIA. Since details of thes... see more

31/12/2025

UC3M

208M€

Project Budget: 208M€

Project leader

UNIVERSIDAD CARLOS III DE MADRID No se ha especificado una descripción o un objeto social para esta compañía.

total researchers 1339

PARTICIPATION DEPralty Sin fecha límite de participación.

Ver 33 Participantes

Financing granted El organismo H2020 notifico la concesión del proyecto The day 2019-12-12

IMI2-2018-15-08: AMR Accelerator programme Pillar B:... Specific Challenge:There are significant scientific challenges to the discovery and development of n...

I+D

Cerrada does 6 years

0% 43% 100%

characteristics of the participant

Este proyecto no cuenta con búsquedas de partenariado abiertas en este momento.

Private Information

No hay información privada compartida para este proyecto. Habla con el coordinador.

33 Participantes

UC3M

6.53M€ | Leader

NOVEDADES AGRICOLAS

285.68K€ | participant

JANSSEN PHARMACEUTICA NV

14.70M€ | participant

INSTITUT DE RECERCA DE L`HOS...

277.50K€ | participant

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Project duration: 72 months Date Start: 2019-12-12
End date: 2025-12-31

Project leader

UNIVERSIDAD CARLOS III DE MADRID No se ha especificado una descripción o un objeto social para esta compañía.

total researchers 1339

Project Budget 208M€

participation deadline Sin fecha límite de participación.

Project description The European Regimen Accelerator for Tuberculosis (ERA4TB) has the explicit goal of developing a new combination therapy to treat all forms of TB starting from ~20 leads and drug candidates provided by EFPIA. Since details of these are as yet unavailable, we will implement an agile drug development algorithm that entails profiling and portfolio construction. Profiling involves characterisation and ranking molecules in preclinical studies comprising in vitro drug combination assays, hollow fiber and single cell analysis, innovative murine and non-human primate models, PK/PD studies, combined with biomarker discovery and non-invasive NIR or PET/CT imaging to monitor disease progression and response to treatment. Modelling, simulation and artificial intelligence tools will help progress compounds from early preclinical to clinical development and to predict drug exposure, human doses and the best combinations. After extensive preclinical profiling, selected compounds will enter portfolio development for first time in human tests and phase I clinical trials in order to ensure that they are safe, well-tolerated and bioavailable with negligible drug-drug interactions. If needed, formulation studies will be conducted to improve pharmacological properties. ERA4TB has assembled the best expertise and resources available in Europe, to build a highly effective and sustainable drug development consortium with a flexible and dynamic management system to execute the profiling and portfolio strategy, aided by clearly defined go/no-go decision points. The expected outcome of ERA4TB is a series of highly active, bactericidal, orally available drugs to constitute two or more new combination regimens with treatment-shortening potential ready for Phase II clinical evaluation. These regimens will be compatible with drugs used to treat common comorbidities, such as HIV-AIDS and diabetes, and should impact UN Sustainable Development Goal 3, namely, ending TB by 2030.

Conecta tu I+D

Entra hoy

Forgot your password?

Financing

Companies

CTIs/Universidades

Projects

researchers